|
|
|
|
| LEADER |
03172nam a22005175i 4500 |
| 001 |
978-84-938062-7-9 |
| 003 |
DE-He213 |
| 005 |
20151204172322.0 |
| 007 |
cr nn 008mamaa |
| 008 |
121026s2011 sp | s |||| 0|eng d |
| 020 |
|
|
|a 9788493806279
|9 978-84-938062-7-9
|
| 024 |
7 |
|
|a 10.1007/978-84-938062-7-9
|2 doi
|
| 040 |
|
|
|d GrThAP
|
| 050 |
|
4 |
|a RA427.8
|
| 072 |
|
7 |
|a MBN
|2 bicssc
|
| 072 |
|
7 |
|a MED076000
|2 bisacsh
|
| 082 |
0 |
4 |
|a 613
|2 23
|
| 082 |
0 |
4 |
|a 614.44
|2 23
|
| 100 |
1 |
|
|a García-Fontes, Walter.
|e author.
|
| 245 |
1 |
0 |
|a Incentives for Research, Development, and Innovation in Pharmaceuticals
|h [electronic resource] /
|c by Walter García-Fontes.
|
| 264 |
|
1 |
|a Madrid :
|b Springer Healthcare Iberica :
|b Imprint: Springer Healthcare,
|c 2011.
|
| 300 |
|
|
|a IX, 96 p.
|b online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 347 |
|
|
|a text file
|b PDF
|2 rda
|
| 490 |
1 |
|
|a Economía de la Salud y Gestión Sanitaria
|
| 505 |
0 |
|
|a Introduction -- Incentives for innovation: a survey -- Incentives for innovation: neglected diseases -- When patents are not enough: supplementary incentives for pharmaceutical innovation -- The Contribution of the United States, Europe and Japan in Discovering New Drugs: 1982 2003 -- The use of pay for performance for drugs: can it improve incentives for innovation? -- Drug Price Regulation: Recent Trends and Downstream Neglected Issues.
|
| 520 |
|
|
|a Incentives for innovation are particularly relevant in the pharmaceutical industry where not all social needs provide equally profitable opportunities and where most OECD countries try to implement diffe - rent measures that promote research in these less profitable areas. The lack of incentives for innovation is especially dramatic when we take into account diseases affecting mostly low-income countries, and also diseases affecting small groups of patients. How can incentives be provided to deal with these less profitable acti - vities when no clear markets exist for the innovations being introduced? Some of the contributions of this book go into discussing alternative mechanisms to substitute for these inexistent markets, and situations where traditional instruments such as public procurement or direct subsidies have proven totally insufficient. Also, this book discusses the clear mismatch between the size of the markets being targeted and the incentives being provided.
|
| 650 |
|
0 |
|a Medicine.
|
| 650 |
|
0 |
|a Health promotion.
|
| 650 |
|
0 |
|a Health informatics.
|
| 650 |
|
0 |
|a Health economics.
|
| 650 |
|
0 |
|a Medical economics.
|
| 650 |
1 |
4 |
|a Medicine & Public Health.
|
| 650 |
2 |
4 |
|a Health Promotion and Disease Prevention.
|
| 650 |
2 |
4 |
|a Health Economics.
|
| 650 |
2 |
4 |
|a Health Informatics.
|
| 650 |
2 |
4 |
|a Medicine/Public Health, general.
|
| 710 |
2 |
|
|a SpringerLink (Online service)
|
| 773 |
0 |
|
|t Springer eBooks
|
| 776 |
0 |
8 |
|i Printed edition:
|z 9788493806217
|
| 830 |
|
0 |
|a Economía de la Salud y Gestión Sanitaria
|
| 856 |
4 |
0 |
|u http://dx.doi.org/10.1007/978-84-938062-7-9
|z Full Text via HEAL-Link
|
| 912 |
|
|
|a ZDB-2-SME
|
| 950 |
|
|
|a Medicine (Springer-11650)
|
